Farhad Ravandi-Kashani
M.D. Anderson Cancer Center · MD Anderson · UT MD Anderson Cancer Center
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Farhad Ravandi-Kashani as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 12:36 UTC. Open this list on ClinicalTrials.gov
- Ph1NCT06021600 · A Phase 1, Open-Label, Sequential Cross-over, Bioavailability/Bioequivalence Study to Compare the Pharmacokinetics of Oral Cladribine With the Reference Listed Drug, Intravenous CladribineM.D. Anderson Cancer Center · terminated · Leukemia, Myelodysplastic Syndromes, Acute Myeloid Leukemia · principal investigator
- Ph1/Ph2NCT05010122 · ASTX727, Venetoclax, and Gilteritinib for the Treatment of Newly Diagnosed, Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic SyndromeM.D. Anderson Cancer Center · recruiting · Acute Myeloid Leukemia, Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia · principal investigator
- Ph2NCT04746235 · Venetoclax and ASTX727 for the Treatment of Relapsed, Refractory, or Newly Diagnosed Acute Myeloid LeukemiaM.D. Anderson Cancer Center · active not recruiting · Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia · principal investigator
- Ph1/Ph2NCT03576547 · Venetoclax, Ponatinib, and Dexamethasone in Participants With Philadelphia Chromosome or BCR-ABL Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Chronic Myelogenous LeukemiaM.D. Anderson Cancer Center · terminated · Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Philadelphia Chromosome Positive, Recurrent Acute Lymphoblastic Leukemia · principal investigator
- Ph1NCT03048344 · A Phase I, Two-part Study to Determine the Recommended Dose and Evaluate the Safety and Tolerability of a Novel Oral Arsenic Trioxide Formulation (ORH-2014) in Subjects With Advanced Hematological DisordersOrsenix LLC · completed · Advanced Hematological Disorders · principal investigator
- Ph1/Ph2NCT02464657 · Study of Idarubicin, Cytarabine, and Nivolumab in Patients With High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)M.D. Anderson Cancer Center · completed · Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndrome · principal investigator
- Ph1/Ph2NCT02257138 · Ruxolitinib Phosphate and Decitabine in Treating Patients With Relapsed or Refractory or Post Myeloproliferative Acute Myeloid LeukemiaM.D. Anderson Cancer Center · completed · Blasts More Than 20 Percent of Bone Marrow Nucleated Cells, Blasts More Than 20 Percent of Peripheral Blood White Cells, Myelodysplastic/Myeloproliferative Neoplasm · principal investigator
- Ph2NCT02196857 · Sorafenib Plus 5-Azacitidine Initial Therapy of Patients With Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MS) With FLT3-ITD MutationM.D. Anderson Cancer Center · completed · Leukemia · principal investigator
- Ph1/Ph2NCT02089230 · MEK Inhibitor 162 Relapsed and/or Refractory Acute Myeloid Leukemia (AML) and Poor Prognosis, Not Suitable for or Unwilling to Receive Standard TherapyM.D. Anderson Cancer Center · terminated · Leukemia · principal investigator
- Ph1NCT01891981 · Study of Moxetumomab Pasudotox in Patients With Relapsed and/or Refractory Acute Lymphoblastic Leukemia (ALL)M.D. Anderson Cancer Center · terminated · Leukemia · principal investigator
- Ph2NCT01786343 · Decitabine for Older or Unfit Patients With Acute Myeloid Leukemia (AML)M.D. Anderson Cancer Center · completed · Leukemia · principal investigator
- Ph2NCT01409161 · Tretinoin and Arsenic Trioxide With or Without Gemtuzumab Ozogamicin in Treating Patients With Previously Untreated Acute Promyelocytic LeukemiaM.D. Anderson Cancer Center · recruiting · Acute Promyelocytic Leukemia With PML-RARA · principal investigator
- Ph1/Ph2NCT01254890 · Sorafenib and 5-Azacitidine in Acute Leukemia + Myelodysplastic SyndromeM.D. Anderson Cancer Center · completed · Leukemia · principal investigator
- Ph1NCT00981240 · Dose Escalation, Safety and Pharmacokinetic Study of SAR103168 in Patients Refractory/ Relapsed Acute Leukemias or High-risk Myelodysplastic SyndromesSanofi · completed · Acute Myelogenous Leukemia · principal investigator
- Ph2NCT00792948 · Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic LeukemiaNational Cancer Institute (NCI) · active not recruiting · Acute Lymphoblastic Leukemia, Adult B Acute Lymphoblastic Leukemia, Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 · principal investigator
- Ph2NCT00778375 · Clofarabine Plus Low-Dose Cytarabine Induction and Decitabine Consolidation in Frontline Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS)M.D. Anderson Cancer Center · completed · Acute Myeloid Leukemia, Myelodysplastic Syndrome · principal investigator
- Ph2NCT00674479 · INCB018424 in Patients With Advanced Hematologic MalignanciesM.D. Anderson Cancer Center · completed · Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, Myelodysplastic Syndrome · principal investigator
- Ph1NCT00642031 · Triciribine Phosphate Monohydrate (TCN-PM, VD-0002) in Adult Patients With Advanced Hematologic MalignanciesPrescient Therapeutics, Ltd. · completed · Hematologic Malignancies, Leukemia · principal investigator
- Ph1/Ph2NCT00542971 · Phase I-II Study of Idarubicin, Cytarabine, and Sorafenib (BAY43-9006)M.D. Anderson Cancer Center · completed · AML, Acute Myeloid Leukemia, Myelodysplastic Disorders · principal investigator
- Ph2NCT00501826 · Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic LymphomaM.D. Anderson Cancer Center · recruiting · T Acute Lymphoblastic Leukemia, T Lymphoblastic Lymphoma · principal investigator
- Ph2NCT00453193 · Alemtuzumab and Pentostatin In T-cell NeoplasmsM.D. Anderson Cancer Center · terminated · Lymphoma, Leukemia · principal investigator
- Ph2NCT00422591 · Standard Idarubicin and Cytarabine for the Treatment of Acute Myeloid Leukemia (AML)M.D. Anderson Cancer Center · completed · Leukemia, Acute Myeloid Leukemia, AML · principal investigator
- Ph2NCT00413166 · All-trans Retinoic Acid, and Arsenic +/- IdarubicinM.D. Anderson Cancer Center · completed · Acute Promyelocytic Leukemia · principal investigator
- Ph2NCT00412594 · Cladribine and Rituximab in Treating Patients With Hairy Cell LeukemiaM.D. Anderson Cancer Center · recruiting · Hairy Cell Leukemia, Recurrent Hairy Cell Leukemia · principal investigator
- Ph2/Ph3NCT00398983 · Randomized Study of Decitabine in Maintenance Therapy of Acute Myeloid Leukemia (AML)M.D. Anderson Cancer Center · completed · Acute Myelogenous Leukemia · principal investigator
- Ph2NCT00390793 · Combination Chemotherapy and Dasatinib in Treating Participants With Philadelphia Positive or BCR-ABL Positive Acute Lymphoblastic Leukemia.M.D. Anderson Cancer Center · completed · Acute Lymphoblastic Leukemia, BCR-ABL1 Fusion Protein Expression, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive · principal investigator
- Ph1NCT00301769 · SJG-136 in Treating Patients With Relapsed or Refractory Acute Leukemia, Myelodysplastic Syndromes, Blastic Phase Chronic Myelogenous Leukemia, or Chronic Lymphocytic LeukemiaNational Cancer Institute (NCI) · terminated · Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12) · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 12:36 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- SWOG Network Group Operations Center of the NCTNU10CA180888 · NCI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI DAWN HERSHMAN, PRIMO N. LARA · fiscal years 2014 to 2026Named on NCT00792948
- Southwest Oncology Group Treatment GrantU10CA032102 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI CHARLES D. BLANKE · fiscal years 1985 to 2013Named on NCT00792948
- Phase I Studies of Targeted Anti-Cancer TherapiesU01CA062461 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI James C Yao · fiscal years 1994 to 2013Named on NCT00301769
Most cited trial papers
PubMed returned no clinical-trial papers for this author name in childhood acute lymphoblastic leukemia.